Andrea Allersdorfer

USPTO Granted Patents = 26 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 7.4

ph-index = 3

Forward Citations = 51(Granted Patents)

Location History:

Freising, DE (2018 - 2021)
Geisenhausen, DE (2015 - 2022)
Wolnzach, DE (2019 - 2023)

Company Filing History:

17 out of 36

Pieris Pharmaceuticals Gmbh

Daiichi Sankyo Company, Limited

patents

4. 1 out of 832,680

Other

patents

Years Active: 2015-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195503 - Proteins specific for CD137 (2025-01-14),

2. 11773147 - Lipocalin muteins with binding affinity for LAG-3 (2023-10-03),

3. 11345728 - Specific-binding polypeptides and uses thereof (2022-05-31),

4. 11261221 - Proteins specific for CD137 (2022-03-01),

5. 11168119 - Lipocalin muteins with binding affinity for LAG-3 (2021-11-09),

6. 11034738 - Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2) (2021-06-15),

7. 11034737 - Proteins specific for calcitonin gene-related peptide (2021-06-15),

8. 10947284 - Fusion molecules (2021-03-16),

9. 10927156 - Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response (2021-02-23),

10. 10927154 - Multi-specific polypeptide useful for localized tumor immunomodulation (2021-02-23),

11. 10787491 - Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) (2020-09-29),

12. 10774119 - Specific-binding polypeptides and uses thereof (2020-09-15),

13. 10526384 - Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof (2020-01-07),

14. 10526382 - Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof (2020-01-07),

15. 10501510 - Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof (2019-12-10),

Title: Innovations by Andrea Allersdorfer in Pharmaceutical Applications

Introduction

Andrea Allersdorfer, located in Wolnzach, Germany, is an accomplished inventor with a remarkable portfolio of 26 patents. His groundbreaking work primarily focuses on developing novel lipocalin muteins that have significant implications in the pharmaceutical field, particularly for cancer and autoimmune diseases.

Latest Patents

Among his latest innovations, Allersdorfer has developed specific proteins for CD137. These human lipocalin muteins are engineered to bind with CD137 and hold potential as anti-cancer agents and immune modulators. The patents also cover methods of creating these lipocalin muteins and the therapeutic applications associated with them. Additionally, he has invented lipocalin muteins with binding specificity for LAG-3, designed to inhibit the binding of LAG-3 to MHC class II on overexpressing cells. This discovery also opens new avenues for treatment and prevention of various human diseases.

Career Highlights

Allersdorfer's professional journey includes significant contributions at prominent organizations such as Pieris Pharmaceuticals GmbH and Sanofi. His expertise in biochemistry and molecular biology has greatly influenced the direction of research in the development of therapeutic agents.

Collaborations

Throughout his career, Andrea has collaborated with notable colleagues including Alexander Wiedenmann and Christine Rothe. Their combined efforts have contributed to the successful advancement of innovative solutions in the pharmaceutical industry.

Conclusion

Andrea Allersdorfer exemplifies the spirit of innovation in biotechnology through his extensive research and patent portfolio. His focus on creating novel lipocalin muteins not only showcases his capabilities as an inventor but also promises to make a significant impact in the treatment of serious human diseases. The ongoing development of his patents will undoubtedly continue to inspire future research and applications in the medical field.

This text is generated by artificial intelligence and may not be accurate.